• In February 2026, Tenet Healthcare reported fourth-quarter 2025 results with revenue rising to US$5,527 million and net income increasing to US$371 million, while issuing 2026 guidance that points to higher net income and earnings per share versus 2025.
• Beneath the headline numbers, management highlighted continued expansion of its higher-margin ambulatory surgery business and a completed Conifer Health Solutions transaction as key earnings drivers.
• Against this backdrop, we’ll examine how Tenet’s emphasis on growing its ambulatory surgery segment could shape the company’s broader investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Tenet Healthcare's Investment Narrative?

To own Tenet Healthcare today, you have to buy into a story of mix shift: a hospital operator leaning harder into higher‑margin ambulatory surgery while simplifying the rest of the portfolio. The latest quarter, with revenue up to US$5,527 million and net income at US$371 million, reinforced that message and was followed by 2026 guidance that points to higher net income and earnings per share versus 2025. The completed Conifer Health Solutions transaction and a sizable buyback program, which has retired just over 10% of shares, both feed into a cleaner, more focused equity story and helped fuel the recent double‑digit share price move. In the near term, execution in ambulatory growth and integration of recent deals look like the key catalysts, while high leverage, volatile profit margins and insider selling sit near the top of the risk list.

However, investors should also be aware of how Tenet’s high debt load could constrain flexibility. Tenet Healthcare's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$211 million to above US$648 million, underscoring how far apart individual views can be. When you set that against Tenet’s debt burden and the market’s focus on ambulatory surgery growth, it highlights why many market participants are rethinking what could realistically drive the next phase of performance.

Explore 4 other fair value estimates on Tenet Healthcare - why the stock might be worth over 2x more than the current price!

Build Your Own Tenet Healthcare Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tenet Healthcare research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Tenet Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tenet Healthcare's overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.